Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients

Table 1 Demographic and clinical characteristics of patients before liver transplantation

	Everolimuspatients(n = 30)	CNI patients(n = 30)	P value
Male	24 (80)	24 (80)	1.000
Age (yr)	46 (44-60)	51 (44-59)	0.760
Etiology of liver disease
EtOH	16 (53.3)	13 (43.3)	0.541
HCV	11 (36.7)	10 (33.3)
HBV	0	2 (6.7)
Autoimmune	1 (3.3)	2 (6.7)
Hemochromatosis	1 (3.3)	2 (6.7)
Cholestatic disorders	1 (3.3)	0
Cryptogenic	0	1 (3.3)
Time from LT (mo)	75 (16-113)	72 (17-108)	0.859
Indication for LT
HCC	2 (6.7)	4 (13. 3)	0.041
Decompensated cirrhosis	16 (53.3)	21 (70)
Decompensated cirrhosis and HCC	12 (40)	4 (13.3)
Acute liver Failure	0	1 (3.3)
Donor age (yr)	55 (34-72)	49 (31-63)	0.521
Early allograft dysfunction	5 (16.7 )	2 (6.7)	0.212

Categorical variables are expressed as absolute n (%), continuous variables are expressed as medians and interquartillic range. CNI: Calcineurin inhibitors; HCV: Hepatitis C virus; HBV: Hepatitis B virus; LT: Liver transplantation; HCC: Hepatocarcinoma.